New Mountain Abandons Matt Holt's $32B Vision, Prioritizing Control Over Disruption

The deal is officially dead. New Mountain Capital has pulled the plug on talks with former executive Matt Holt over a proposed $32 billion buyout of five healthcare tech portfolio companies. The firm ended negotiations in a client letter, citing unresolved governance issues and the prolonged process becoming a distraction for management. This isn't just a stalled conversation; it's a clear signal about where the firm's priorities lie.

The numbers tell the story. The proposal, which would have created a new venture called Thoreau, was backed by significant financing, including more than $12 billion of debt financing from JPMorgan Chase and Goldman Sachs. For New Mountain, the exit would have delivered a substantial haul, with $14 billion of proceeds and about $8.5 billion in gross gains. Yet the firm chose to walk away, retaining control of assets that could have been worth billions.

This termination reveals a critical shift in capital allocation. New Mountain is prioritizing internal control and governance stability over a potentially disruptive, high-value spin-off led by a visionary insider. The firm's cited reasons-governance concerns and distraction-mask a deeper preference for maintaining the status quo. By keeping these five companies, New Mountain preserves its direct oversight and the ability to manage them as a portfolio, rather than handing them over to an external operator, even one with deep roots in the firm.

For smart money, this is a classic case of skin in the game versus a clean exit. Matt Holt, who spent over two decades at New Mountain, had the vision and the backing to build something new. His departure and the deal's collapse suggest the firm's leadership sees more value in retaining control than in backing a proven insider's ambitious plan. The termination is a vote for internal management over external, visionary leadership.

The Smart Money's Calculus: Skin in the Game vs. Skin in the Game

The proposed deal was a classic insider-led carve-out, but the numbers reveal a stark imbalance in who truly stood to lose. For New Mountain Capital, the exit was a clean, low-risk proposition. The firm would have pocketed $14 billion in proceeds, broken down as $12 billion in cash and about $2 billion in equity in the new buyer, plus warrants. That's a guaranteed haul, with the firm's capital effectively evaporating from its books while its funds walked away with a gross gain of about $8.5 billion.

For Matt Holt, the picture was entirely different. His skin in the game was his own capital and reputation. He was raising funds in the Middle East, backed by ICG Plc, to finance the $30+ billion purchase. Yet, when the deal collapsed, his personal financial exposure-his equity stake and the value of his time-vanished with it. New Mountain retained control of the assets and its own capital, while Holt's ambitious plan, and his potential personal gain, were left on the table.

A key red flag for institutional investors is the lack of transparency. Despite the deal's scale and the involvement of a former firm president, Holt did not respond to a request for comment. This silence from the lead operator is a classic warning sign. It suggests a disconnect between the deal's public narrative and the private reality, making it harder for outside capital to assess the true alignment of interest.

The outcome underscores the fundamental difference in risk profiles. New Mountain's capital was protected, its gains locked in. Holt's capital was exposed, his vision unproven. In the end, the smart money's calculus favors the firm that kept its skin in the game, not the one that bet everything on a deal that never closed.

Institutional Backing & Financing: Who's Really in the Whale Wallet?

The proposed deal had serious institutional muscle behind it. For Matt Holt's new venture, Thoreau, the key financial anchor was alternative asset manager ICG Plc. This firm was backing the venture, signaling that at least one major player in the alternative capital space saw potential in the healthcare tech/AI platform Holt envisioned. That's a vote of confidence from a smart money player who understands the long-term bet on digital health infrastructure.

The debt pipeline was even more substantial. Major Wall Street firms were lining up to provide the massive leverage needed for a $30+ billion purchase. JPMorgan Chase and Goldman Sachs were preparing more than $12 billion in debt financing for the deal. This wasn't a pipe dream; it was a concrete financial structure being built, with the two biggest names in investment banking committed to the transaction. For the proposed new entity, this was the fuel for its growth engine.

The collapse of the deal terminated that entire institutional backing and debt pipeline. The $12 billion in committed Wall Street debt evaporated, along with the strategic partnership from ICG Plc. This is a major loss for any new entity that would have been built on that foundation. It means the smart money that was aligned with Holt's vision-both the equity from ICG and the debt from the banks-has walked away. The termination doesn't just kill a deal; it severs the financial lifeline that was supposed to power the new company's launch.

What's Next for the Portfolio & What to Watch

With the $32 billion deal dead, New Mountain Capital is left holding the cards. The firm has not ruled out future moves, but its current position is one of cautious retention. In its client letter, New Mountain stated it may still evaluate different structures for the five healthcare tech assets, including keeping them separate or combining some of them in future transactions. This is a deliberate pause, not a permanent holding pattern. The firm is signaling it will keep its options open, but for now, it has chosen to maintain control.

The primary risk for investors watching this portfolio is the potential for stagnation. These assets-Datavant, Swoop, Machinify, Smarter Technologies, and Office Ally-were brought together by a visionary insider with a clear AI-driven platform strategy. By walking away from that plan, New Mountain has removed a powerful catalyst for aggressive innovation and strategic integration. The assets now remain under the firm's direct control, which could lead to a more conservative, siloed management approach. Without the pressure of a unified, ambitious new venture, the incentive to break down internal barriers or pursue bold new markets may weaken.

The key watchpoint for smart money is simple: does New Mountain follow through on its stated openness to future combinations? Any move to merge some of these five companies would be a major signal. It would indicate the firm sees value in unlocking synergies it previously deemed too complex or distracting. Conversely, if the company keeps them separate and unchanged, it confirms a preference for stability over transformation. For investors, the next catalyst will be any announcement of a new transaction involving these assets-a move that would prove the firm's earlier stance was not just about governance, but about preserving its own control.